DME

Featured

Identifying biomarkers to guide DME treatment

Elisabetta Pilotto MD, FEBO, speaking at the EURETINA 2021 Virtual Congress on Identifying biomarkers to guide DME treatment.

2021 Virtual

Prize Papers 2: Vascular Diseases & Diabetic Retinopathy I – Design and Rationale of the YOSEMITE and RHINE Trials: Two Phase 3 Studies of Faricimab in Patients With Diabetic Macular Edema

Presenter: Marta S. Figueroa

2021 Virtual

Prize Papers 2: Vascular Diseases & Diabetic Retinopathy I – Exploring Ang-2 Signalling in Vascular Stability in Patients With DME Receiving Faricimab in Phase 2 and Phase 3 Trials

Presenter: Anat Loewenstein

2021 Virtual

Prize Papers 2: Vascular Diseases & Diabetic Retinopathy I – Changes in macular perfusion following treatment of diabetic macular edema with intravitreal anti-vascular endothelial growth factor agents

Presenter: Colin Tan

Video

Prize Papers 2: Vascular Diseases & Diabetic Retinopathy I – Intravitreal aflibercept for the treatment of patients with diabetic macular edema in routine clinical practice in Latin America: The AQUILA study

Presenter: Francisco J Rodriguez

2021 Virtual

EURETINA Session 3: Diabetic Retina – Imaging biomarkers guiding DME treatment

Presenter: Elisabetta Pilotto

Video

Prize Papers 5: Imaging I – Comparison of mydriatic and nonmydriatic handheld retinal imaging with early treatment diabetic retinopathy study (ETDRS) 7-standard field photography for diabetic retinopathy (DR) and diabetic macular edema (DME)

Presenter: Recivall Salongcay

Video

Prize Papers 7: Vascular Diseases & Diabetic Retinopathy II – Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema: One-Year Results From the Phase 3 YOSEMITE and RHINE Trials

Presenter: Ramin Tadayoni

Video

Prize Papers 7: Vascular Diseases & Diabetic Retinopathy II – A Novel Bicyclic Peptide Inhibitor of Plasma Kallikrein, THR-149, for the Treatment of Diabetic Macular Edema (DME): Clinical and Pre-Clinical Evidence

Presenter: Francesco Bandello

Video

IME: AMD and DME Treatment Innovations: Home Monitoring, Artificial Intelligence Diagnostics and Extended Duration Anti-VEGF Therapeutics – Welcome and ARS

Presenter: Anat Loewenstein

Video

IME: AMD and DME Treatment Innovations: Home Monitoring, Artificial Intelligence Diagnostics and Extended Duration Anti-VEGF Therapeutics – Review of EURETINA AMD & DME clinical trends survey data

Presenter: Anat Loewenstein

Video

IME: AMD and DME Treatment Innovations: Home Monitoring, Artificial Intelligence Diagnostics and Extended Duration Anti-VEGF Therapeutics – The Anti-VEGF treatment burden

Presenter: Sebastian Wolf

Video

IME: AMD and DME Treatment Innovations: Home Monitoring, Artificial Intelligence Diagnostics and Extended Duration Anti-VEGF Therapeutics – Current and future applications of longer lasting Anti-VEGF therapeutics

Presenter: Ramin Tadayoni

Video

IME: AMD and DME Treatment Innovations: Home Monitoring, Artificial Intelligence Diagnostics and Extended Duration Anti-VEGF Therapeutics – Insights and pearls on implantable sustained release technologies

Presenter: Carl Awh

Video

IME: AMD and DME Treatment Innovations: Home Monitoring, Artificial Intelligence Diagnostics and Extended Duration Anti-VEGF Therapeutics – Artificial Intelligence (AI) in nAMD & DME treatment decision-making

Presenter: Anat Loewenstein

Secretariat Address
European Society of Retina Specialists
Reinacherstrasse 131
4053 Basel
Switzerland

T +41 61 686 77 91
F +41 61 686 77 88

Email: [email protected]

EURETINA 2025 Paris

Special Focus Meeting 2025

Ophthalmologica

Opportunities

Memberships

Code of Conduct

Privacy Policy

Newsletter Sign up

Follow us

© EURETINA 2024 All rights reserved